Skip Navigation



Annals of Oncology Advance Access published online on November 4, 2005
Annals of Oncology, doi:10.1093/annonc/mdj053
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/2/286    most recent
mdj053v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Avilés, A.
Right arrow Articles by Nambo, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Avilés, A.
Right arrow Articles by Nambo, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received May 22, 2005
Revised September 13, 2005
Accepted September 26, 2005

original article

Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy

A. Avilés 1*, N. Neri 2, and M. J. Nambo 2

1 Oncology Research Unit, Oncology Hospital National Medical Center, IMSS, México, D.F. Mexico
2 Department of Hematology, Oncology Hospital National Medical Center, IMSS, México, D.F. Mexico

* To whom correspondence should be addressed.
A. Avilés, E-mail: agustin.aviles{at}imss.gob.mx


  Abstract

Background: The use of anthracyclines in patients with cancer has been associated with the presence, even when standard doses were employed, of cardiac toxicity, most frequently after 5 years of therapy.Treatment of cancer during pregnancy remains a dilemma because cytotoxic therapy has been associated with the presence of severe side-effects. The outcome of children that received antracyclines during pregnancy, including during the first trimester, remain unknown because long-term follow-up is not available.

Patients and methods: Eighty-one children whose mothers (29 acute leukemia, 33 malignant lymphoma and 19 Hodgkin's disease) were treated with cytotoxic drugs, including anthracyclines, during pregnancy were evaluated to detect cardiac toxicity, including clinical evaluation and echocardiogram [all parameters were evaluated, but fraction shortening (FS) was taking as the best parameter to evaluate cardiac toxicity in children] every 5 years after birth until 29 years of age.

Results: Children with actual age of 9.3-29.5 years (mean 17.1) did not show any clinical date of cardiac disfunction, in all cases echocardiogram was normal and FS did not showed any abnormality during the follow-up.

Conclusions: The use of anthracyclines did not show any clinical or echocardiogram evidence of late cardiac toxicity. We hope that the present report increases the number of reports of the long-term follow-up of children who received cytotoxic drugs, in order to define the best treatment in this special patient setting.

Keywords: acute leukemia; cardiac toxicity; Hodgkin's disease; malignant lymphoma; pregnancy: complicated.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 haematolHome page
D. Pereg, G. Koren, and M. Lishner
The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy
Haematologica, September 1, 2007; 92(9): 1230 - 1237.
[Abstract] [Full Text] [PDF]

Home page
 ASH-SAPHome page
K. R. McCrae, D. C. Matthews, and M. Linenberger
Consultative hematology
ASH Self-Assessment Program, January 1, 2007; 2007(1): 466 - 505.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.